Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.

Critical reviews in oncology/hematology - 1 Jan 2022

Bunduc Stefania, Gede Noémi, Váncsa Szilárd, Lillik Veronika, Kiss Szabolcs, Dembrovszky Fanni, Eróss Bálint, Szakács Zsolt, Gheorghe Cristian, Mikó Alexandra, Hegyi Péter

Abstract excerpt

This systematic review and meta-analysis evaluated the prognostic role of cell-free DNA (cfDNA) in pancreatic ductal adenocarcinoma (PDAC). Eligible studies reported differences in overall (OS) and progression-free survival (PFS) by cfDNA status. The random effect model yielded the pooled hazard ratios (HRs) and 95 % confidence intervals (CI). Detection of circulant-tumor DNA (ctDNA), KRAS mutations and other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell-Free Nucleic Acids

Share to DNA, Neoplasm

Share to Mutation

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 34843928
DOI: 10.1016/j.critrevonc.2021.103548

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.PMID 34843928Read ↗

Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations.Semantic proximity Read ↗

Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlationsSemantic proximity Read ↗

Circulating Cell-Free DNA fragmentomics distinguishes pancreatic ductal adenocarcinoma from non- malignant conditionsSemantic proximity Read ↗

Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.Semantic proximity Read ↗

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancerSemantic proximity Read ↗

Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?Semantic proximity Read ↗

Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic CancerSemantic proximity Read ↗

Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysisSemantic proximity Read ↗

KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.Semantic proximity Read ↗

Development and Validation of a Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic CancerSemantic proximity Read ↗

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Semantic proximity Read ↗

Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.